There are no trials yet as all companies are currently racing to be the first to have DAAs approved for HCV monoinfection, and therefore achieving primacy in this huge market (the HCV market will grow by at least 100% as previously untreatable patients, or treatment failures, will now become treatable). The mode of action, however, will not be affected by the presence or not of other viruses.
forget hcv, concentrate on hiv, page-10
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
